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Introduction: High mammographic density is an established breast cancer risk factor, and circulating oestrogen
influences oestrogen-regulating gene expression in breast cancer development. However, less is known about the
interrelationships of common variants in the CYP19A1 gene, daily levels of oestrogens, mammographic density
phenotypes and body mass index (BMI) in premenopausal women.
Methods: Based on plausible biological mechanisms related to the oestrogen pathway, we investigated the
association of single nucleotide polymorphisms (SNPs) in CYP19A1, 17β-estradiol and mammographic density
in 202 premenopausal women. DNA was genotyped using the Illumina Golden Gate platform. Daily salivary
17β-estradiol concentrations were measured throughout an entire menstrual cycle. Mammographic density
phenotypes were assessed using a computer-assisted method (Madena). We determined associations using
multivariable linear and logistic regression models.
Results: The minor alleles of rs749292 were positively (P = 0.026), and the minor alleles of rs7172156 were
inversely (P = 0.002) associated with daily 17β-estradiol. We observed an 87% lower level of daily 17β-estradiol
throughout a menstrual cycle in heavier women (BMI >23.6 kg/m2) of rs7172156 with minor genotype aa
compared with major genotype AA. Furthermore, the rs749292 minor alleles were inversely associated with
absolute mammographic density (P = 0.032). Lean women with rs749292 minor alleles had 70 to 80% lower
risk for high absolute mammographic density (>32.4 cm2); Aa: odds ratio (OR) = 0.23 (95% CI 0.07 to 0.75).
Lean women with rs7172156 minor homozygous genotype had OR 5.45 for high absolute mammographic
density (aa: OR = 5.45 (95% CI 1.13 to 26.3)).
Conclusion: Our findings suggest that two SNPs in CYP19A1, rs749292 and rs7172156, are associated with
both daily oestrogen levels and mammographic density phenotypes. BMI may modify these associations, but
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Sex hormones, in particular oestrogens, are associated
with breast cancer development in both pre- and post-
menopausal women [1-3], and circulating oestrogens have
been shown to influence oestrogen-regulating gene ex-
pression [4]. CYP19A1 is a member of the cytochrome
P450 family and is involved in the bioconversion of andro-
stenedione to oestrone and of testosterone to estradiol [5].
Human CYP19A1 is a protein commonly known as aro-
matase and is a gene product of CYP19A1, which is
located on chromosome 15q21.2 [6]. In humans, aroma-
tase is expressed in the gonads, adipose tissue and other
sites, although the primary site of oestrogen production in
premenopausal women is the ovaries [5]. Breast adipose
tissue produces oestrogen locally, which may be increased
in pre- and postmenopausal obese women [7], owing to
higher levels of proinflammatory cytokines such as tumour
necrosis factor, a known inducer of aromatase [8,9].
Importantly, the gene CYP19A1 is polymorphic, and the
presence of single-nucleotide polymorphisms (SNPs) in
the gene may alter aromatase activity, thereby causing var-
iations in the levels of oestrogens [10].
Endogenous oestrogen has been shown to be both in-
versely [11,12], and positively [13-15] associated with
mammographic density, and both high absolute and per-
cent mammographic density have consistently been associ-
ated with breast cancer development [16,17]. Furthermore,
mammographic density phenotypes are a strong heritable
biomarker of breast cancer development, and twins studies
suggest that genetic factors account for 30% to 60% of its
variance [18,19]. In a recent meta-analysis including five
genome-wide association studies, a variant (rs10995190)
in the ZNF365 gene, which promotes genome stability
during DNA damage, was associated with both breast can-
cer risk and mammographic density [20]. However, this
SNP explains only 0.5% of the variance of mammographic
density, and many other loci may be involved in predicting
mammographic density phenotypes and breast cancer de-
velopment [20].
Mammographic density is also influenced by several well-
known major breast cancer risk factors such as age, body
mass index (BMI), parity, and hormone therapy [21]. Previ-
ous studies have observed an inverse association between
BMI and premenopausal breast cancer development
[22,23]. In contrast, weight gain in early adult life has been
associated with postmenopausal breast cancer develop-
ment [24], but the association between weight gain and
premenopausal breast cancer development has not yet
been clarified [25]. However, premenopausal abdominal
adiposity has been associated with oestrogen receptor–
negative (ER−) breast cancer [26]. Studies also support
excess weight being associated with higher oestrogen
levels and ER+ postmenopausal breast cancer develop-
ment [27,28]. In addition, we have previously shown thatsalivary estradiol concentrations are positively associated
with BMI throughout the menstrual cycle in premeno-
pausal women [29].
Few studies have been focused on genetic susceptibility,
daily levels of oestrogen and premenopausal mammo-
graphic density, but plausible biological mechanisms may
exist because functional genetic polymorphisms in the aro-
matase gene CYP19A1 have been associated with higher
estradiol levels. Therefore, the main aim of the present
study was to elaborate whether hypothesis-driven selected
common variants in the CYP19A1 gene are associated
with daily 17β-estradiol levels and mammographic density
phenotypes among healthy premenopausal women and
whether BMI modifies these associations.
Methods
A total of 204 women ranging in age from 25 to 35 years
participated in the Norwegian Energy Balance and Breast
cancer Aspects I study (EBBA-I) from 2000 to 2002 at
the Department of Clinical Research, University Hospital
of North Norway, Tromsø (UNN) [30]. Women meeting
the following eligibility criteria were included: self-reported
regular menstruation (normal cycle length, 22 to 38 days
within the previous 3 months), no ongoing use of steroid
contraceptives, no pregnancy or lactation in the previous
6 months, no history of gynaecological disorders and no
chronic disorders (for example, diabetes, hypo- or hyper-
thyroidism). Two women were excluded because of miss-
ing mammographic data, resulting in 202 participants
being included in the present study.
Participants’ characteristics, including reproductive and
lifestyle factors, were collected by one trained nurse using
questionnaires and interviews at the time of recruitment.
Recall and memory-probing aids, including a lifetime cal-
endar, were used to date specific life events. Questionnaires
(filled out by the participant and interviewer, administered
by trained personnel) were used to collect information
about birth weight, age at menarche, marital status, educa-
tion, ethnicity, reproductive history, lifetime total physical
activity, previous use of hormonal contraceptives and fam-
ily history of cancer, smoking and alcohol. Dietary data
were collected on 7 different days during the menstrual
cycle (days 3 to 6 and 21 to 23) using a previously vali-
dated, precoded food diary [31]. Daily average energy and
nutrient intake were computed.
Clinical parameters
Participants attended three study visits during one men-
strual cycle: first visit, days 1 to 5 of the menstrual cycle,
early follicular phase; second visit, days 7 to 12, late follicu-
lar phase; and third visit, days 21 to 25, late luteal phase.
Measurements included height to the nearest 0.5 cm and
weight (in light clothing) to the nearest 0.1 kg on a regu-
larly calibrated electronic scale. BMI in kilograms per
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blood samples were drawn at all three scheduled visits dur-
ing the menstrual cycle.
Assessment of oestrogen
Serum concentrations of 17β-estradiol were measured in fresh
sera for all three collection points using a direct immuno-
metric assay (Immuno-1; Bayer Diagnostics, Norway)
at the Department of Clinical Chemistry, UNN [30]. The
sensitivity was 0.01 nmol/L, and the coefficient of vari-
ation (CV) was 3.9%.
To assess the bioavailable fraction of 17β-estradiol, the
participants collected daily saliva samples during one
menstrual cycle, preferably in the morning, starting on the
first day of menstrual bleeding according to previously
established and validated collection protocols developed
at the Reproductive Ecology Laboratory of Harvard
University [32] and according to the manufacturer’s
protocol [30]. The samples were stored at −70°C. All sam-
ples were run in duplicate, and samples from the same
cycles were run within the same assay. The assays were
done in different batches at Harvard University. 17β-
estradiol concentrations were measured in daily saliva sam-
ples using a 125I-based radioimmunoassay kit (no. 39100;
Diagnostic Systems Laboratory, Webster, TX, USA). All
cycles were aligned to the day of ovulation, based on the
identification of the 17β-estradiol drop, which provides a
reasonable estimate of the day of ovulation [33,34]. The
midcycle 17β-estradiol drop could not be made for 14 of
the included women, and their cycles were not aligned.
Overall mean salivary 17β-estradiol concentration was cal-
culated for all participants, whereas an additional index of
mean menstrual estradiol on days −7 to +6 was calculated
for the 188 women with aligned cycles. The sensitivity of
the 17β-estradiol salivary assay was 4 pmol/L, and the
average intra-assay CV was 9%. The measurements of
17β-estradiol had a higher CV at the start and end of the
menstrual cycle, and the interassay CV ranged from 23%
(low pool) to 13% (high pool). Furthermore, there were
higher rates of missing data at the end of the cycle, so we
included aligned measurements of salivary 17β-estradiol
from day −7 to day +6 in this study.
Assessment of mammographic density
Bilateral two-view mammograms were obtained from
women during the second scheduled visit (between cycle
days 7 and 12) at the Centre of Breast Imaging, UNN,
using a standard protocol [30]. The left craniocaudal mam-
mograms were digitised and imported into a computerised
mammographic density assessment programme (Madena)
developed at the University of Southern California School
of Medicine (Los Angeles, CA, USA) [35,36]. The density
measurements were conducted by one trained reader
(GU), and the total breast area was determined by aresearch assistant trained by GU. The total breast area
was defined using a special outlining tool, and the size of
this area in square centimetres using the Madena soft-
ware. To assess density, the reader outlined a region of
interest (ROI), excluding the pectoralis muscle, prominent
veins and fibrous strands. The reader applied a tinting tool
to pixels considered to represent dense areas of the mam-
mograms within the ROI. The Madena software calcu-
lated the size of this dense area in square centimetres.
Absolute mammographic breast density represented this
dense area, and the percentage mammographic density
was the ratio of absolute mammographic breast density to
total breast area multiplied by 100. The mammograms
were read in four batches, with an equal number of mam-
mograms included in each batch. A duplicate reading of
26 randomly selected mammograms from two of the
batches showed a Pearson’s correlation coefficient of 0.97.
The reader was blinded to any characteristics of the study
population.
Single-nucleotide polymorphism selection and genotyping
We analysed CYP19A1 genetic polymorphisms that en-
code the aromatase enzyme. Blood samples from 204
women in the EBBA-I study were frozen at −70°C. DNA
was extracted from whole blood using a MagAttract DNA
Blood Mini M48 kit (QIAGEN, Valencia, CA, USA) by the
Department of Medical Genetics, UNN. DNA was geno-
typed on the Golden Gate Platform (Illumina, San Diego,
CA, USA) at the Fred Hutchinson Cancer Research Center
(Makar Lab), using the manufacturer’s protocol. In brief,
250 ng of genomic DNA was divided into aliquots in
96-well plates, processed accordingly and scanned on the
Illumina iScan reader using BeadStudio software.
We conducted a series of quality control procedures [37].
SNP call rates exceeded 99% for this study, with 100% con-
cordance of blinded duplicates. The linkage disequilibrium
select algorithm was employed to choose the tag SNPs
via the Genome Variation Server [38,39]. The SNPs were
selected using an r2 threshold of 0.8 and a minor al-
lele frequency >5%, representing variability in the white
European population. Tag SNP coverage extended 2 kilo-
bases (kb) upstream and 1 kb downstream of the gene, and
29 SNPs were covered. We further reduced the number of
SNPs using power calculations and ended up with a final
selection of eight common SNPs with minor allele fre-
quency >0.2: rs10046, rs17703883, rs2414097, rs2445761,
rs4646, rs7172156, rs727479 and rs749292 (see Additional
file 1). None of the selected SNPs was monomorphic or
significantly out of Hardy–Weinberg equilibrium.
Covariate analytes
Serum concentrations of total cholesterol were determined
enzymatically using cholesterol esterase and cholesterol
oxidase. High-density lipoprotein cholesterol (HDL-C) was
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ethylene glycol and dextran sulphate.
Statistical methods
On the basis of the plausible biological mechanisms re-
lated to the oestrogen pathway, we investigated the asso-
ciations between eight SNPs in the CYP19A1 gene,
hormone levels (salivary midmenstrual 17β-estradiol and
serum 17β-estradiol) and mammographic density pheno-
types (total breast area, absolute mammographic density,
percent mammographic density and nondense breast
area) using multivariable linear regression models. Asso-
ciations were assessed for the selected SNPs, and the se-
lected SNPs were coded as AA = 0 (major homozygous),
Aa = 1 (heterozygous) and aa = 2 (minor homozygous)
and were included as ordinal variables in the models.
We compared the linear response between the categor-
ies of genotypes by including indicator variables for Aa
and aa, using AA as the reference.
Age, parity and BMI are known to be associated with
mammographic density phenotypes, are possibly associ-
ated with hormone levels and/or CYP19A1 variants, and
were therefore considered as potential confounders and
included as covariates in all models [21]. Furthermore, the
models with mammographic density as the dependent
variable also included salivary 17β-estradiol and serum
HDL-C, both of which are known to influence mammo-
graphic density [40,13]. In the final analyses, we focused
on two selected SNPs (rs7172156 and rs749292) and
stratified the women by major, heterozygous and minor
genotypes. We then compared the genotype groups using
different characteristics of the study population (lifestyle
factors, anthropometric measures, serum blood sampling
and salivary hormone sampling), and we used one-way
analysis of variance for continuous variables and the χ2
test for categorical variables.
The multivariable logistic regression models were run
using median absolute mammographic density (32.4 cm2)
and median percent mammographic density (28.5%) as
cutoff values. Mammographic density was used as a
dependent variable, and rs7172156 and rs749292 were
used as independent variables, adjusted for age, parity and
BMI. In addition, we analysed in detail whether BMI vari-
ations influenced our results (that is, tertiles/dichotomised
BMI), but only dichotomised BMI by median BMI values
gave additional information and thus were included in the
final analysis.
We used linear mixed models for repeated measures
to study variations of daily salivary 17β-estradiol across
the menstrual cycle for subgroups of women with major,
minor homozygous or heterozygous genotypes in the
SNPs rs7172156 and rs749292, and we then adjusted for
age, BMI and parity. The Toeplitz covariance structure
gave the best fit to the data and was used in all models.Our candidate polymorphisms were based on plausible
biological hypotheses, and all P-values were two-tailed
and considered significant when the value was <0.05. The
analyses were conducted with SPSS version 21.0 software
(IBM, Armonk, NY, USA).
Ethical considerations
All participants underwent informed consent procedures
and signed a consent form. The study was approved
by the Norwegian Data Inspectorate and the Regional
Committee for Medical Research Ethics.
Results
The participating premenopausal women had mean values
(standard deviation (SD)) for age of 30.7 (3.07) years and
BMI of 24.4 (3.77) kg/m2 (Table 1). When we stratified
the women into groups for rs749292 and rs7172156 by
major homozygous, heterozygous and minor homozygous
genotypes, we observed no differences in lifestyle factors,
anthropometric measures or serum analytes (Table 1).
We observed an association between two SNPs (rs749292,
rs7172156) and both salivary estradiol and absolute mam-
mographic density. Moreover, a positive association was
observed between rs749292 and midmenstrual salivary
17β-estradiol (P = 0.026), and an inverse association be-
tween rs7172156 and midmenstrual salivary 17β-estradiol
(P = 0.002), after adjustment for age, BMI and parity
(Table 2). We also observed a negative association be-
tween rs749292 and absolute mammographic density
(P = 0.032) after adjusting for age, BMI, parity, salivary
midmenstrual 17β-estradiol and serum HDL-C.
rs749292, rs7172156 and oestrogen levels
The associations between rs749292 and rs7172156 with
17β-estradiol were studied further with multivariable lin-
ear regression analyses. For rs749292, we observed a posi-
tive association between the minor homozygous genotype
(aa) and salivary 17β-estradiol (β = 3.79, P = 0.03). For
rs7172156, we observed an inverse association between the
minor homozygous genotype and salivary 17β-estradiol
(β = −6.96, P < 0.001) (Table 2). We then dichotomized
participants by median split of BMI (23.6 kg/m2). For
rs7172156, the minor homozygous genotype (aa) was in-
versely associated with 17β-estradiol levels (aa: β = −10.2,
P < 0.001) in women with a high BMI (>23.6 kg/m2)
(Table 3).
No clear association was observed between any of
these SNPs and serum levels of 17β-estradiol at any of
the three measured time periods (early follicular, late fol-
licular or late luteal phase) of the menstrual cycle. In the
mixed linear regression models, we found that women
with different genotypes of rs7172156 varied in the levels
of average midmenstrual salivary 17β-estradiol (P = 0.001).
Among women with genotype AA and genotype Aa,
Table 1 Characteristics of the Norwegian EBBA-I study population overall and by CYP19A1 single-nucleotide
polymorphisms rs7172156 and rs749292
Study
characteristics
Overall
means (SD)
rs7172156 rs749292
Major
genotype, AA
Heterozygous
genotype, Aa
Minor
genotype, aa
P-valueb Major
genotype, AA
Heterozygous
genotype, Aa
Minor
genotype, aa
P-valueb
(n = 82)a (n = 91)a (n = 31)a (n = 62 )a (n = 93)a (n = 48)a
Age (yr) 30.7 (3.07) 30.2 (3.09) 31.1 (3.12) 30.7 (2.79) 0.149 30.5 (2.99) 31.0 (3.17) 30.4 (3.00) 0.425
Education (total yr) 16.1 (3.01) 15.9 (2.65) 16.2 (3.41) 16.3 (2.73) 0.701 15.8 (3.02) 16.3 (3.15) 16.2 (2.70) 0.603
Reproductive factorsc
Age at menarche (yr) 13.1 (1.36) 13.1 (1.40) 13.2 (1.43) 13.1 (1.04) 0.793 13.0 (1.14) 13.2 (1.52) 13.2 (1.20) 0.536
Menstrual cycle
length (days)
28.3 (3.42) 28.7 (3.01) 28.2 (3.66) 27.8 (3.69) 0.463 28.0 (3.48) 28.3 (3.50) 28.8 (3.22) 0.503
Number of children 0.91 (1.13) 0.85 (1.17) 0.98 (1.11) 0.84 (1.10) 0.721 0.73 (1.01) 0.99 (1.12) 0.98 (1.28) 0.320
Weight at birth (g) 3,389 (561) 3,428 (554) 3,369 (585) 3,343 (519) 0.701 3,274 (574) 3,507 (530) 3,328 (556) 0.024
Clinical parameters
BMI (kg/m2)d 24.4 (3.77) 24.4 (3.74) 24.2 (3.73) 25.0 (4.00) 0.606 24.8 (4.66) 24.1 (3.19) 24.3 (3.33) 0.467
Total tissue fat (%)
(DXA)e
34.2 (7.62) 33.9 (7.69) 33.7 (7.92 36.0 (6.41) 0.328 35.1 (8.10) 33.5 (7.51) 33.9 (7.08) 0.455
Serum samplesf
Total cholesterol
(mmol/L)
4.45 (0.78) 4.55 (0.84) 4.36 (0.75) 4.40 (0.71) 0.268 4.45 (0.77) 4.33 (0.79) 4.68 (0.76) 0.044
HDL-C (mmol/L) 1.54 (0.33) 1.55 (0.30) 1.54 (0.36) 1.51 (0.34) 0.833 1.53 (0.32) 1.54 (0.36) 1.55 (0.31) 0.940
Serum hormonesf
Estradiol (nmol/L) 0.15 (0.06) 0.15 (0.06) 0.15 (0.07) 0.14 (0.06) 0.644 0.14 (0.06) 0.15 (0.07) 0.14 (0.06) 0.646
SHBG (nmol/L) 51.9 (19.5) 51.7 (18.1) 52.7 (22.0) 50.2 (15.3) 0.828 51.6 (17.0) 53.3 (22.8) 50.0 (15.5) 0.626
Salivary hormonesg
Midmenstrual
estradiol (pmol/L)
18.2 (8.98) 19.4 (9.52) 19.0 (8.81) 12.6 (5.39) 0.001 16.3 (7.67) 18.4 (9.59) 19.8 (9.03) 0.095
Lifestyle factorsc
Current smokers (%) 22.3 19.3 22.8 28.1 0.586 13.8 23.2 10.8 0.768
Alcohol (U/wk) 2.89 (3.38) 3.03 (3.41) 2.84 (3.38) 2.67 (3.38) 0.865 2.52 (3.07) 3.07 (3.41) 3.08 (3.74) 0.561
Energy intake
(kJ/day)
8,093 (1,900) 8,371 (1,837) 8,085 (1,754) 7,381 (2,314) 0.046 7,749 (1,975) 8,087 (2,005) 8,495 (1,480) 0.123
Previous use of
OC (%)
83.4 81.9 85.7 81.2 0.747 81.0 83.9 85.7 0.788
Leisure time MET
(hr/wk)
57.6 (88.6) 68.2 (133) 48.4 (32.0) 56.7 (42.9) 0.337 51.9 (39.4) 63.4 (125) 53.6 (36.8) 0.685
Mammographic
densitye
Total area (cm2) 137 (62.5) 131 (64.9) 137 (59.6) 155 (62.8) 0.209 149 (69.5) 132 (61.1) 129 (52.6) 0.161
Absolute density
(cm2)
34.7 (23.4) 34.7 (22.4) 32.8 (23.8) 40.7 (24.4) 0.283 39.1 (26.2) 33.5 (23.8) 32.3 (17.4) 0.238
Percent density (%) 29.8 (19.0) 31.5 (19.0) 28.6 (20.4) 28.8 (14.5) 0.594 30.1 (18.1) 29.8 (20.2) 29.9 (17.9) 0.995
Numbers in parentheses are standard deviations (SDs). BMI, body mass index; E2, 17β-estradiol; DXA, Dual-energy X-ray absorptiometry; HDL-C, High-density
lipoprotein-cholesterol; LDL-C, Low-density lipoprotein-cholesterol; MET, Metabolic equivalent; OC, Oral contraceptives; SHBG, Sex hormone-binding globulin.
aNumbers may vary due to missing information. bOneWay ANOVA or χ2 test, significance level P < 0.05. cQuestionnaires. dMeasurements at days 1 to 5 after onset
of menstrual cycle. eMeasurements at days 7 to 12 after onset of menstrual cycle. fSerum samples in early follicular phase: days 1 to 5 after onset of menstrual
cycle. gDaily salivary samples throughout one entire menstrual cycle.
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higher mean 17β-estradiol levels were observed, respect-
ively (Figure 1d). This association was even more marked
when we dichotomised the data by median split of BMI
(23.6 kg/m2). We observed an 87% lower level of mean17β-estradiol throughout a menstrual cycle in heavier
women (BMI >23.6 kg/m2) with minor genotype aa of
rs7172156 compared with those with major genotype AA
(Figure 1f). Among women with genotype AA, heavier
women had a 33% higher level of 17β-estradiol compared
Table 2 Associations between two CYP19A1 single-nucleotide polymorphisms (rs749292, rs7172156) and 17β-estradiol
CYP19A1 SNPs Location Frequencies Genotype β-value (95% CI) P-value
rs749292 Intron
Salivary 17β-estradiol 0.283 AA Reference
0.457 Aa 2.73 (−0.22, 5.68) 0.069
0.26 aa 3.79 (0.39, 7.20) 0.029
P-value for trend 0.026
Serum 17β-estradiol AA Reference
Aa 6.77 (−13.4, 26.9) 0.509
aa 0.73 (−22.8, 24.2) 0.951
P-value for trend 0.905
rs7172156 Intron
Salivary 17β-estradiol 0.406 AA Reference
0.444 Aa −0.10 (−2.76, 2.56) 0.939
0.15 aa −6.96 (−10.6, −3.32) <0.001
P-value for trend 0.002
Serum 17β-estradiol AA Reference
Aa −3.38 (−22.1, 15.3) 0.722
aa −12.4 (−38.1, 13.2) 0.340
P-value for trend 0.365
Multivariable linear regression model adjusted for age, parity and body mass index. β: Estimated slope coefficient (for example, change in response) from reference (AA)
to Aa and aa; CI, Confidence interval; SNP, Single-nucleotide polymorphism. Salivary midmenstrual estradiol is the average of aligned menstrual estradiol levels from
days −7 to +6. Serum 17β-estradiol was measured from early follicular phase days 1 to 5.
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increase in 17β-estradiol levels when we compared leaner
and heavier women. When comparing mean 17β-estradiol
levels in lean women (BMI ≤23.6 kg/m2) with rs749292
major genotype AA with heavier women (BMI >23.6 kg/m2)
with rs749292 minor genotype aa, a 52% higher mean
17β-estradiol level was observed (Figure 1).
rs749292 and rs7172156 and mammographic density
phenotypes
The association between the SNPs and mammographic
density phenotypes was studied with multivariable linear
regression models. For rs749292, we observed an inverse
association between minor alleles (Aa, aa) and absolute
mammographic density (Table 4). We observed a posi-
tive association between rs7172156 minor genotype aa
and absolute mammographic density.
After dichotomising by median split of BMI, we found
that rs749292 minor alleles were inversely associated with
absolute mammographic density (Aa: β = −13.0, P = 0.006;
aa: β = −14.1, P = 0.010) in lean women (≤23.6 kg/m2), but
not in women with a BMI >23.6 kg/m2. Among lean
women (≤23.6 kg/m2) with rs7172156 genotype aa, we
observed a positive association with absolute mammo-
graphic density (aa: β = 18.2, P = 0.005) (Table 4).
In the multivariable logistic regression models, lean
women (BMI ≤23.6 kg/m2) who had rs749292 minoralleles (Aa, aa) had an 80% lower risk for high percent
mammographic density (above median: >28.5%) (Aa:
OR = 0.19 (95% CI, 0.05 to 0.82); aa: OR = 0.17 (95% CI
0.03 to 0.82)). The results were similar but attenuated
for absolute mammographic density (Table 5).
For rs7172156, lean women with a minor homozygous
genotype had a 5.45 higher OR for high absolute mammo-
graphic density (aa: OR = 5.45 (95% CI, 1.13 to 26.3)).
Similar associations were observed for rs7172156 and per-
cent mammographic density (Table 5).
Discussion
In the present study of premenopausal women, two SNPs
(rs749292, rs7172156) of eight studied in the CYP19A1
gene were related to both daily salivary 17β-estradiol and
mammographic density phenotypes. The association with
mammographic density was revealed when we used saliv-
ary 17β-estradiol as a covariate, and similar results were
observed for absolute and percent mammographic dens-
ity. Furthermore, our results suggest that body weight may
modify these associations. We observed an 87% lower
level of daily 17β-estradiol throughout a menstrual cycle
in heavier women (BMI >23.6 kg/m2) with minor genotype
aa (17β-estradiol 12.3 pmol/L) of rs7172156 compared
with major genotype AA (17β-estradiol 22.4 pmol/L). Fur-
thermore, lean women with rs7172156 minor homozygous
genotype aa had a fivefold higher OR for high absolute
Table 3 Associations between the CYP19A1 single-nucleotide
polymorphisms (rs749292, rs7172156) and 17β-estradiol by
median body mass index (23.6 kg/m2)
Genotype β-value (95% CI) P-value
rs749292
Salivary 17β-estradiol
BMI ≤23.6 kg/m2 AA Reference
Aa 2.72 (−1.06, 6.50) 0.157
aa 2.79 (−1.54, 7.12) 0.203
P-value for trend 0.197
BMI >23.6 kg/m2 AA Reference
Aa 3.08 (−1.79, 7.96) 0.212
aa 5.26 (−0.32, 10.8) 0.064
P-value for trend 0.059
rs7172156
Salivary 17β-estradiol
BMI ≤23.6 kg/m2 AA Reference
Aa 0.78 (−2.63, 4.19) 0.650
aa −3.98 (−9.11, 1.14) 0.126
P-value for trend 0.326
BMI >23.6 kg/m2 AA Reference
Aa −1.26 (−5.62, 3.11) 0.569
aa −10.2 (−15.7, −4.68) <0.001
P-value for trend 0.001
Multivariable linear regression model adjusted for age, body mass index (BMI)
and parity. β: Estimated slope coefficient (for example, change in response)
from reference value (AA) to Aa and aa. Salivary midmenstrual 17β-estradiol is
the average of aligned menstrual estradiol levels from days −7 to +6.
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genotype AA. Lean women who had rs749292 minor al-
leles had 70% to 80% lower risk for high absolute and high
percent mammographic density compared with major
homozygous genotype AA.
The CYP19 activity is responsible for the bioconver-
sion of androgens to oestrogens [5,6], and to our know-
ledge, there have been few studies related to CYP19A1
SNPs, daily levels of oestrogen throughout an entire
menstrual cycle and mammographic density phenotypes
in premenopausal women. It is not clear why and how
noncoding SNPs influence the gene activity, but previous
genome-wide association studies have shown intronic
SNPs to be important breast cancer risk loci [41]. This
does not necessarily imply that the SNPs are causal, but it
may help to identify novel susceptibility loci. In addition,
intronic SNPs may regulate gene expression through en-
dogenous trans-acting factors, epigenetics and chromo-
some conformation [42]. Our results are in part supported
by a previous report [10] that rs749292 minor alleles were
associated with a 10% to 20% increase in oestrogen levels
among postmenopausal women in a combined analysis of
five cohort studies. Other SNPs in the CYP19A1 gene havealso been studied, and in one study on postmenopausal
women with a mean age of 57 years and a mean BMI of
24.2 kg/m2, researchers found an association with circulat-
ing oestrogen levels, but only among women with BMI
>25 kg/m2 [43]. Interestingly, functional genetic polymor-
phisms may also influence the level of estradiol in women
undergoing inhibitory treatment, as two CYP19A1 SNPs
were associated with higher estradiol levels, particularly
after initiation of aromatase inhibitors [44]. These findings
imply that CYP19A1 SNPs may be of clinical interest, as
aromatase inhibitor treatment has been shown to be one
of the most effective modern antihormonal breast cancer
treatment regimens. To our knowledge, no clear associa-
tions have been observed between CYP19A1 SNPs and
mammographic density [45], and researchers in one study
found no associations of oestrogen synthesis or oestrogen
metabolism genes with mammographic density in a mixed
population of perimenopausal, young postmenopausal and
postmenopausal women [45]. Few known genetic variants
predict both mammographic density and breast cancer
risk, but Lindstrom et al. found an association between
common variants in the ZNF365 gene, which promotes
genome stability under DNA damage, with both mammo-
graphic density and breast cancer development [20]. In
addition, SNPs in the inflammatory gene interleukin-6
(IL-6) have recently been associated with premenopausal
percent mammographic density [46]. Despite the clear
association of endogenous oestrogens with breast cancer
development [1], results have been inconsistent regarding
associations between CYP19A1 variants and risk for breast
cancer [10,47-49], but rs1008805 [50] and, recently, rs10046
were observed to be associated with breast cancer suscepti-
bility among premenopausal women [51].
Elevated BMI has been related to higher levels of sex hor-
mones in both premenopausal [30] and postmenopausal
women [52], and weight loss through diet and exercise may
reduce sex steroid hormone levels in premenopausal [53]
and postmenopausal women [54]. We previously observed
that CYP17 polymorphisms were associated with 17β-
estradiol levels, especially in women with unfavourable
metabolic profiles [55]. Interestingly, in the present study,
an inverse association was observed between rs749292
minor alleles and absolute mammographic density among
lean women, but this association disappeared in heav-
ier women. Furthermore, rs7172156 minor alleles were
associated with higher absolute mammographic density
among lean women. In contrast, we found that among
women with minor alleles and high BMI, rs7172156 may
be a protective polymorphism associated with lower
17β-estradiol and lower OR for having above-median per-
cent mammographic density (>28.5%) and absolute mam-
mographic density (>32.4 cm2). Similar mammographic
threshold estimates of 25% mammographic density and
32-cm2 absolute mammographic density have been shown
Figure 1 Mean salivary 17β-estradiol levels across menstrual cycles for rs749292 and rs7172156, adjusted for age, body mass index
and parity. (a) rs749292 mean estradiol levels: minor homozygous genotype (aa) (n = 46), 19.8 pmol/L; heterozygous genotype (Aa) (n = 86),
18.7 pmol/L; and major homozygous genotype (AA) (n = 57), 16.0 pmol/L (P = 0.075). (b) rs749292 and low body mass index (BMI ≤23.6 kg/m2):
aa (n = 25), 17.5 pmol/L; Aa (n = 46), 17.4 pmol/L; and AA (n = 25), 14.7 pmol/L (P = 0.294). (c) rs749292 and high BMI >23.6 kg/m2: aa (n = 21),
22.3 pmol/L; Aa (n = 40), 19.9 pmol/L; and AA (n = 30), 17.6 pmol/L (P = 0.265). (d) rs7172156 mean estradiol levels: aa (n = 29), 12.3 pmol/L; Aa
(n = 83), 19.2 pmol/L; and AA (n = 78), 19.3 pmol/L (P = 0.001). (e) rs7172156 and low BMI ≤23.6 kg/m2: aa (n = 12), 12.9 pmol/L; Aa (n = 41), 17.5
pmol/L; and AA (n = 45), 16.9 pmol/L (P = 0.208). (f) rs7172156 and high BMI >23.6 kg/m2: aa (n = 17), 12.0 pmol/L; Aa (n = 42), 20.9 pmol/L; and
AA (n = 33), 22.4 pmol/L (P = 0.001).
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ment within 5 to 10 years [56,57].
Interestingly, a previous study observed an association
between rs7172156, rs749292 [58] and serum levels of hep-
atocyte growth factor (HGF). HGF is a cytokine derived
from adipose tissue [58] that promotes cell migration, pro-
liferation and invasion, and previous studies have found
associations between HGF levels and development from
benign breast disorders to preinvasive, basal-like breast
cancer [59], as well as further correlations with poor prog-
nosis. These findings lead us to hypothesize that there may
be a biological rational for the associations we observed for
two SNPs in CYP19A1: rs7172156 and rs749292.
Our study has several strengths. These are inclusion of
premenopausal women; clinical measurements carefully
timed to the menstrual cycle, including mammographicdensity phenotypes and serum and daily saliva 17β-
estradiol; and a validated computer-assisted method for
quantifying mammographic density. In contrast, we did
not observe the same associations between these two
SNPs in CYP19A1 and serum 17β-estradiol as we did for
salivary 17β-estradiol. Importantly, salivary 17β-estradiol
was assessed daily, is the free bioavailable fraction and is
not bound to albumin or sex hormone-binding globulin,
in contrast to the serum 17β-estradiol levels, and may in
part explain the variations observed [30,33]. Previous re-
search has indicated that single measurements of serum
oestrogen do not accurately reflect women’s long-term
oestrogen levels [3], whereas multiple measurements of
unbound bioavailable levels probably give a picture of
the real endogenous cumulative exposure over time.
This means that single measurements are likely to be an
Table 4 Association between CYP19A1 single-nucleotide polymorphisms (rs749292 and rs7172156) and mammographic
density phenotypes, overall and stratified by median body mass index (23.6 kg/m2)
Mammographic
density
Total BMI ≤23.6 BMI >23.6
Genotype β-value (95% CI) P-value β-value (95% CI) P-value β-value (95% CI) P-value
(n = 202) (n = 101) (n = 101)
rs749292
Absolute density AA Reference Reference Reference
Aa −7.78 (−15.5, −0.12) 0.047 −13.0 (−22.2, −3.82) 0.006 1.91 (−9.86, 13.7) 0.748
aa −9.47 (−18.3, −0.61) 0.036 −14.1 (−24.8,−3.44) 0.010 −1.36 (−14.9, 12.2) 0.842
P-value for trend 0.032 0.015 0.587
Percent density AA Reference Reference Reference
Aa −2.64 (−7.68, 2.39) 0.301 −3.01 (−10.0, 4.01) 0.396 2.44 (−3.93, 8.82) 0.449
aa −2.68 (−8.50, 3.14) 0.364 −2.33 (−10.5, 5.81) 0.571 0.42 (−6.92, 7.76) 0.910
P-value for trend 0.348 0.537 0.866
rs7172156
Absolute density AA Reference Reference Reference
Aa 0.27 (−6.70, 7.24) 0.939 3.94 (−4.63, 12.5) 0.363 −4.87 (−15.9, 6.15) 0.768
aa 11.6 (1.43, 21.8) 0.026 18.2 (5.67, 30.8) 0.005 −2.15 (−16.6, 12.3) 0.382
P-value for trend 0.074 0.011 0.978
Percent density AA Reference Reference Reference
Aa −1.52 (−6.09, 3.05) 0.512 1.15 (−5.38, 7.67) 0.728 −4.98 (−10.9, 0.93) 0.097
aa 2.23 (−4.45, 8.91) 0.512 2.01 (−7.57, 11.6) 0.678 −2.26 (−9.99, 5.47) 0.563
P-value for trend 0.792 0.573 0.847
Multivariable linear regression model adjusted for age, parity, body mass index (BMI), 17-β-estradiol and high-density lipoprotein cholesterol. β: Estimated slope
coefficient (for example, change in response) from reference (AA) to Aa and aa. Mammograms were taken within late follicular phase from days 7 to 12.
Table 5 Adjusted odds ratios for above-median absolute mammographic density (>32.4 cm2) and above-median
percent mammographic density (>28.5%) by CYP19A1 single-nucleotide polymorphism and stratified by median
body mass index (23.6 kg/m2)
Mammographic density Genotype Total (n = 202) BMI ≤23.6 (n = 101) BMI >23.6 (n = 101)
OR (95% CI) OR (95% CI) OR (95% CI)
rs749292
Absolute density AA 1.0 1.0 1.0
Aa 0.59 (0.29, 1.22) 0.23 (0.07, 0.75) 1.28 (0.45, 3.63)
aa 0.86 (0.37, 1.98) 0.28 (0.08, 1.05) 2.21 (0.68, 7.15)
Percent density AA 1.0 1.0 1.0
Aa 0.57 (0.25, 1.30) 0.19 (0.05, 0.82) 1.41 (0.42,4.74)
aa 0.64 (0.25, 1.64) 0.17 (0.03, 0.82) 1.85 (0.49,6.99)
rs7172156
Absolute density AA 1.0 1.0 1.0
Aa 0.76 (0.39, 1.48) 1.49 (0.56, 3.97) 0.35 (0.13, 0.94)
aa 1.16 (0.47, 2.88) 5.45 (1.13, 26.3) 0.34 (0.09, 1.25)
Percent density AA 1.0 1.0 1.0
Aa 0.85 (0.40, 1.82) 1.91 (0.64, 5.68) 0.40 (0.13, 1.22)
aa 1.40 (0.51, 3.82) 5.48 (0.92, 32.7) 0.45 (0.11, 1.87)
Multivariable logistic regression adjusted for age, body mass index (BMI) and parity and stratified by median BMI (23.6 g/m2). Major homozygous genotype AA,
heterozygous genotype Aa and minor homozygous genotype aa. Absolute mammographic density with median 32.4 cm2 as cutoff. Percent mammographic
density with median 28.5% as cutoff. CI: Confidence interval; OR: Odds ratio.
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opausal cyclical changes and will be imperfect estimates
of the true pattern [3,60]. Thus, use of exploratory, non-
invasive, repeated sampling of salivary hormones may
provide new knowledge on the true association between
hormones and breast cancer. Moreover, this may in part
explain why circulating oestrogen levels consistently
have been observed to increase risk, as well as risk pre-
diction for invasive postmenopausal breast cancer [61],
but the association between endogenous oestrogen levels
and breast cancer among premenopausal women is less
clear [3]. Today, liquid chromatography-tandem mass
spectrometry, as compared to the immunoassay method,
is a more efficient way of analysing salivary hormones with
higher specificity and sensitivity. However, previous stud-
ies on estradiol measurements, specifically, have shown a
correlation of 0.969 between mass spectrometry and im-
munoassays [62]. However, our sample size was small, and
associations could have been missed by chance. Further-
more, the population was a sample of volunteer partici-
pants and therefore may not be representative of the
source population, but their average BMI and other
lifestyle-related factors and lipid profiles are in accordance
with the population of premenopausal Norwegian women
[63]. A limited number of SNPs were examined, based on
the biological hypothesis that polymorphisms in the
CYP19 gene may influence 17β-estradiol levels and mam-
mographic phenotypes. Even though only eight SNPs were
examined, there is a risk of false-positive results. Never-
theless, our findings are intriguing and support future re-
search in larger sample sizes.
Conclusion
In the present study, we found associations between two
CYP19A1 SNPs (rs7172156 and rs749292) and both daily
17β-estradiol throughout an entire menstrual cycle and
both absolute and percent mammographic density in
premenopausal women, and the results differed between
lean and heavier women. This observation suggests that
there may be genetic influences on these breast cancer
biomarkers and also that the effect of body size may play a
major role. Future research on genetic control of mammo-
graphic density phenotypes and sex hormones should in-
clude exploratory salivary hormone measurements and
take body size and adiposity into account.
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